Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature

ABSTRACT

Gingivitis and periodontitis are common bacterial infections caused by a variety of microorganisms. Despite the microorganisms' roles as etiologic agents, inflammation-induced substances also have crucial parts in the loss of connective tissue and the supporting alveolar bone. Visfatin is a pleiotropic mediator, which acts as growth factor, cytokine, and pre-B-cell colony-enhancing factor. A positive correlation was detected between the serum/plasma levels of visfatin and inflammatory disorders such as diabetes mellitus and cardiovascular disease. In addition, the visfatin level was higher in saliva and the gingival crevicular fluid (GCF) of subjects with periodontal disease. This review defined current, predictable patterns of possible interaction of visfatin with periodontal infection and other systemic diseases, using PubMed and Medline databases searching for articles written in English. Peer-reviewed articles were targeted using the following keywords: “visfatin,” “periodontal disease,” “inflammatory mediator,” and “biomarker.” Available full-text articles were read, and related articles were also scrutinized, while a hand search was also performed. Search was confined to human studies, and articles written in English and published between 1985 and 2016 were selected. It was concluded that periodontal infection and other systemic diseases could be related to the levels of visfatin in GCF, saliva, and serum as a biomarker of these diseases.

Key words:

Biomarker - inflammatory mediator - periodontal disease - visfatin

• REFERENCES

• 1 Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000 2004; 34: 9-21
• 2 Hanes PJ, Krishna R. Characteristics of inflammation common to both diabetes and periodontitis: Are predictive diagnosis and targeted preventive measures possible?. EPMA J 2010; 1: 101-16
• 3 Taba Jr. M, Kinney J, Kim AS, Giannobile WV. Diagnostic biomarkers for oral and periodontal diseases. Dent Clin North Am 2005; 49: 551-71, vi
• 4 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K. et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30
• 5 Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-7
• 6 Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-58
• 7 Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, Kratzsch J. et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010; 391: 376-81
• 8 Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R. et al. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-7
• 9 Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56: 565-70
• 10 Ozmeric N. Advances in periodontal disease markers. Clin Chim Acta 2004; 343: 1-16
• 11 Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis – A review. J Clin Periodontol 2000; 27: 453-65
• 12 Mamali I, Roupas ND, Armeni AK, Theodoropoulou A, Markou KB, Georgopoulos NA. Measurement of salivary resistin, visfatin and adiponectin levels. Peptides 2012; 33: 120-4
• 13 Todorovic T, Dozic I, Vicente-Barrero M, Ljuskovic B, Pejovic J, Marjanovic M. et al. Salivary enzymes and periodontal disease. Med Oral Patol Oral Cir Bucal 2006; 11: E115-9
• 14 Özcan E, Saygun NI, Serdar MA, Kubar A, Bengi VU. Porphyromonas gingivalis and Epstein-barr virus are associated with increased levels of visfatin in gingival crevicular fluid. J Periodontol 2016; 87: 443-51
• 15 Pradeep AR, Raghavendra NM, Sharma A, Patel SP, Raju A, Kathariya R. et al. Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. J Periodontol 2012; 83: 629-34
• 16 Pradeep AR, Raghavendra NM, Prasad MV, Kathariya R, Patel SP, Sharma A. Gingival crevicular fluid and serum visfatin concentration: Their relationship in periodontal health and disease. J Periodontol 2011; 82: 1314-9
• 17 Tabari ZA, Azadmehr A, Nohekhan A, Naddafpour N, Ghaedi FB. Salivary visfatin concentrations in patients with chronic periodontitis. J Periodontol 2014; 85: 1081-5
• 18 Özcan E, Saygun NI, Serdar MA, Kurt N. Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation. Clin Oral Investig 2015; 19: 921-8
• 19 Özcan E, Saygun NI, Ilikçi R, Karslioglu Y, Musabak U, Yesillik S. Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation. Clin Oral Investig 2017; 21: 1113-21
• 20 Raghavendra NM, Pradeep AR, Kathariya R, Sharma A, Rao NS, Naik SB. Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Dis Markers 2012; 32: 383-8
• 21 Abolfazli N, Jabali S, Saleh Saber F, Babaloo Z, Shirmohammadi A. Effect of non-surgical periodontal therapy on serum and salivary concentrations of visfatin in patients with chronic periodontitis. J Dent Res Dent Clin Dent Prospects 2015; 9: 11-7
• 22 Mishra V, Shettar L, Bajaj M, Math AS, Thakur SL. Interlinking periodontitis and type 2 diabetes mellitus by assessment of crevicular visfatin levels in health and in disease before and after initial periodontal therapy. J Clin Diagn Res 2016; 10: ZC67-71
• 23 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 01) S62-9
• 24 Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9
• 25 Hug C, Lodish HF. Medicine. Visfatin: A new adipokine. Science 2005; 307: 366-7
• 26 Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-81
• 27 Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-14
• 28 López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R. et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-5
• 29 Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C. et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2011; 34: 12-5
• 30 Schutte AE, Huisman HW, Schutte R, van Rooyen JM, Malan L, Fourie CM. et al. Adipokines and cardiometabolic function: How are they interlinked?. Regul Pept 2010; 164: 133-8
• 31 Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010; 72: 469-74
• 32 Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007; 157: 437-42
• 33 Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia 2006; 49: 2723-8
• 34 Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-27
• 35 Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: Its role in MMP-2/9 production and activation. Diabetes Care 2008; 31: 758-60
• 36 Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-80